CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab |
| |
Authors: | Petrioli Roberto Licchetta Antonella Roviello Giandomenico Pascucci Alessandra Francini Edoardo Bargagli Gianluca Conca Raffaele Miano Salvatora Tindara Marzocca Giuseppe Francini Guido;Multidisciplinary Oncology Group On Gastrointestinal Tumors |
| |
Institution: | Medical Oncology Unit, University of Siena, Siena, Italy. r.petrioli@ao-siena.toscana.it |
| |
Abstract: | We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |